Group 1 - The company, Beilu Pharmaceutical, announced that its subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] - Iopamidol is a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and vascular imaging [1] - Compared to traditional high-osmolar contrast agents, Iopamidol places a lower burden on patients' kidneys and cardiovascular systems, making it particularly suitable for patients with renal impairment and those at high risk [1] Group 2 - Due to its excellent imaging effects and lower side effects, Iopamidol has become one of the preferred contrast agents in clinical settings [1]

Core Viewpoint - Beilu Pharmaceutical (300016.SZ) announced that its subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Iopamidol [1] Group 1: Product Information - Iopamidol is a raw material for the contrast agent Iopamidol injection, characterized as a low-osmolar, non-ionic, water-soluble contrast agent [1] - Iopamidol injection is widely used in CT enhancement imaging and vascular imaging [1] - Compared to traditional high-osmolar contrast agents, Iopamidol places a lower burden on patients' kidneys and cardiovascular systems, making it particularly suitable for patients with renal impairment and those at high risk [1] Group 2: Clinical Significance - Due to its excellent imaging effects and lower side effects, Iopamidol has become one of the preferred contrast agents in clinical settings [1]

Core Viewpoint - Northland Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Iopamidol, a contrast agent used in medical imaging [1] Company Summary - Northland Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, is now authorized to market Iopamidol, which is a raw material for the Iopamidol injection [1] - Iopamidol is characterized as a low-osmolar, non-ionic water-soluble contrast agent, making it suitable for various imaging procedures [1] Industry Summary - Iopamidol is widely used in CT enhancement imaging and vascular imaging, providing a safer alternative to traditional high-osmolar contrast agents [1] - The agent is particularly beneficial for patients with renal impairment and those at high risk, due to its lower burden on the kidneys and cardiovascular system [1] - Its favorable imaging effects and reduced side effects have made Iopamidol a preferred choice in clinical settings [1]

Core Viewpoint - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has received approval from the National Medical Products Administration for the marketing application of Iopamidol, a contrast agent used in medical imaging [1] Group 1: Company Developments - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has been granted a marketing approval for Iopamidol, which is a raw material for the contrast agent Iopamidol injection [1] - Iopamidol is characterized as a low-osmolar, non-ionic water-soluble contrast agent widely used in CT enhancement imaging and vascular imaging [1]